Anaphylaxis R&D Pipeline Analysis Report, Q4 2020 - ResearchAndMarkets.com

·3-min read

The "Anaphylaxis R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com's offering.

This review describes the pipeline of drugs under development for Anaphylaxis, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Anaphylaxis Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Anaphylaxis disease overview, Anaphylaxis types, Anaphylaxis symptoms, causes, and FDA/EMA approved treatment options.

Anaphylaxis Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Anaphylaxis indication. The report presents near-term and long-term pipeline development trends and potential insights.

Anaphylaxis Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 8 companies. Business profiles and contact details of the companies actively perusing Anaphylaxis pipeline are assessed.

Anaphylaxis R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Anaphylaxis discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Anaphylaxis companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Anaphylaxis pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Anaphylaxis Pipeline Market News and Developments during 2020

The Anaphylaxis industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Anaphylaxis Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Scope and Coverage

  • Anaphylaxis pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

  • Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

  • Company-company partnerships, company-institute partnerships, and investment details of companies are included

  • 8 companies are included including Aquestive Therapeutics Inc, ARS Pharmaceuticals Inc, Bryn Pharma LLC, Insys Therapeutics Inc, JDP Therapeutics Inc, MannKind Corp, Shenox Pharmaceuticals LLC, Stella Pharma Corporation,

  • Disease overview, Pipeline trends, market analysis, and other developments

  • Potential licensing/new business opportunities in Anaphylaxis pipeline market

Highlights

  • Global coverage of companies and pipeline agents

  • 2020 Trends, market analysis, and developments

  • Potential growth opportunities

  • Comprehensive details of drug candidates

Reasons to Buy

  • Drive pipeline research and commercial assessment

  • Assess most promising drug candidates and stay ahead of the competition

  • Strengthen your pipeline through identifying business expansion and acquisition opportunities

  • Develop new candidates based on most focused targets and mechanism of actions

For more information about this report visit https://www.researchandmarkets.com/r/zgqfat

View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006050/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900